Company profile
Nanomerics | Precision Medicines | Pharmaceutical Research and Development
Nanomerics, a world leader in Molecular Engineered Materials creates new medicines using its Molecular Envelope Technology platform a drug delivery technology that enhances drug efficacy, specificity and safety.
Financial period: 1 Oct 2023 to 30 Sep 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
MR01 | Transaction MzQ0NDYxNzU3OGFkaXF6a2N4
Published 25 Nov 2024 06:21
Company registered at Companies House
Nanomerics Ltd (Company Number: 07373043) was founded in September 2010 to develop METDoloron - a leucine5-enkephalin based therapeutic for the treatment of neuropathic pain. The Wellcome Trust funded work on the delivery system - quaternary ammonium palmitoyl glycol chitosan - that also derisked the company's intellectual property portfolio. A grant of £650,000 was received in 2007.
Nanomerics develops ophthalmic nano-enabled medicines and a nanoparticle drug delivery system designed to facilitate the delivery of hydrophobic pharmaceutical products via ocular, oral and nose-to-brain routes.
The company is now attracting revenues and will turn over £0.5 M in 2013.
9 Dec 2024 to 9 Mar 2026
Ocular allergies are widespread, affecting up to a fifth (20 %) of the world's population. Most patients will be helped by current medication available in the pharmacy. However, about 25 % of the sufferers have a more severe and chronic form of the condition (moderate to severe allergic conjunctivitis, MSAC) and are not effectively treated with these medi...
1 Oct 2022 to 30 Sep 2023
Cancer is an incurable disease. Every year there are about 370,000 new cancer cases and 165,000 cancer deaths in the UK. Globally, there are about 20 million new cancer diagnoses and ~10 million deaths every year. These numbers are predicted to rise as we are living longer. It is now estimated that 1 in 2 adults will develop cancer in their lifetime. The ...
1 Jan 2019 to 31 Dec 2019
"Approximately 43% of people in the UK, or around 28 million adults experience pain, which is more than the combined total of those suffering with diabetes, heart disease and cancer. More adults aged 75 or over (62%) experienced pain than those aged 18 to 25 (14.3%) ([https://goo.gl/QvWaW5][0]). Back pain alone costs the NHS £12.3 billion per year; a seri...
1 Aug 2012 to 31 Oct 2014
An estimated 70 - 105 million Americans and around 20% of European adults suffer from severe chronic pain caused by non-malignant (e.g., HIV, post-herpetic or diabetic neuropathy, arthritis and lower back pain) and malignant (70%-90% of advanced cancer cases) conditions. Current therapies are inadequate in 75% of cases of chronic non-malignant pain and ca...
1 May 2011 to 31 Jul 2011
Awaiting Public Summary
